296 related articles for article (PubMed ID: 21593872)
1. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.
Duy C; Hurtz C; Shojaee S; Cerchietti L; Geng H; Swaminathan S; Klemm L; Kweon SM; Nahar R; Braig M; Park E; Kim YM; Hofmann WK; Herzog S; Jumaa H; Koeffler HP; Yu JJ; Heisterkamp N; Graeber TG; Wu H; Ye BH; Melnick A; Müschen M
Nature; 2011 May; 473(7347):384-8. PubMed ID: 21593872
[TBL] [Abstract][Full Text] [Related]
2. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
Hurtz C; Hatzi K; Cerchietti L; Braig M; Park E; Kim YM; Herzog S; Ramezani-Rad P; Jumaa H; Müller MC; Hofmann WK; Hochhaus A; Ye BH; Agarwal A; Druker BJ; Shah NP; Melnick AM; Müschen M
J Exp Med; 2011 Oct; 208(11):2163-74. PubMed ID: 21911423
[TBL] [Abstract][Full Text] [Related]
3. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
5. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
6. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
7. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
[TBL] [Abstract][Full Text] [Related]
8. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
10. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Abdelrasoul H; Vadakumchery A; Werner M; Lenk L; Khadour A; Young M; El Ayoubi O; Vogiatzi F; Krämer M; Schmid V; Chen Z; Yousafzai Y; Cario G; Schrappe M; Müschen M; Halsey C; Mulaw MA; Schewe DM; Hobeika E; Alsadeq A; Jumaa H
Nat Commun; 2020 Jun; 11(1):3194. PubMed ID: 32581241
[TBL] [Abstract][Full Text] [Related]
11. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
12. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
13. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
14. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
Feldhahn N; Henke N; Melchior K; Duy C; Soh BN; Klein F; von Levetzow G; Giebel B; Li A; Hofmann WK; Jumaa H; Müschen M
J Exp Med; 2007 May; 204(5):1157-66. PubMed ID: 17485517
[TBL] [Abstract][Full Text] [Related]
15. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
17. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
18. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.
Notta F; Mullighan CG; Wang JC; Poeppl A; Doulatov S; Phillips LA; Ma J; Minden MD; Downing JR; Dick JE
Nature; 2011 Jan; 469(7330):362-7. PubMed ID: 21248843
[TBL] [Abstract][Full Text] [Related]
19. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
Thomas X; Heiblig M
Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
[TBL] [Abstract][Full Text] [Related]
20. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.
Porazzi P; De Dominici M; Salvino J; Calabretta B
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
